Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer

DNA and Cell Biology

Volumn 34, Issue 3, 2015, Pages 189-200

  Kachakova, Darina ^a   Mitkova, Atanaska ^a   Popov, Elenko ^a   Popov, Ivan ^a   Vlahova, Alexandrina ^a   Dikov, Tihomir ^a   Christova, Svetlana ^a   Mitev, Vanio ^a   Slavov, Chavdar ^a   Kaneva, Radka ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 30C; MICRORNA 375; MICRORNA LET7C; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN141 MICRORNA, HUMAN; MIRN30 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CALIBRATOR; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; GENE EXPRESSION; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; YOUNG ADULT;

EID: 84923069716     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2014.2663     Document Type: Article

References (113)

1. Albertsen, P.C. (1998). Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280, 975-980.
2. Ambs, S., Prueitt, R.L., Yi, M., Hudson, R.S., Howe, T.M., Petrocca, F., et al. (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68, 6162-6170.
3. Antenor, J.A., Roehl, K.A., Eggener, S.E., Kundu, S.D., Han, M., and Catalona, W.J. (2005). Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 66, 156-160.
4. Avissar, M., Christensen, B.C., Kelsey, K.T., and Marsit, C.J. (2009). MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15, 2850-2855.
5. Backer, H. (1999). Prostate cancer screening: exploring the debate. Permanente J 3, 330-340.
6. Barry, M.J. (2001). Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344, 1373-1377.
7. Bartel, D. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
8. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
9. Benner, M.F., Ballabio, E., van Kester, M.S., Saunders, N.J., Vermeer, M.H., Willemze, R., et al. (2012). Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides. Exp Dermatol 21, 632-634.
10. Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14, 1271-1277.
11. Brase, J.C., Johannes, M., Schlomm, T., Falth, M., Haese, A., Steuber, T., et al. (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128, 608-616.
12. Brase, J.C., Wuttig, D., Kuner, R., and Sultmann, H. (2010). Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9, 306.
13. Bryant, R.J., Pawlowski, T., Catto, J.W., Marsden, G., Vessella, R.L., Rhees, B., et al. (2012). Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106, 768-774.
14. Busacca, S., Germano, S., De Cecco, L., Rinaldi, M., Comoglio, F., Favero, F., et al. (2010). MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 42, 312-319.
15. Catto, J.W., Alcaraz, A., Bjartell, A.S., De Vere White, R., Evans, C.P., Fussel, S., et al. (2011). MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59, 671-681.
16. Cava, C., Bertoli, G., Ripamonti, M., Mauri, G., Zoppis, I., Della Rosa, P.A., et al. (2014). Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. PLoS One 9, e97681.
17. Chang, X., Li, S., Li, J., Yin, L., Zhou, T., Zhang, C., et al. (2014). Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations. J Diabetes Res 2014, 761938.
18. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 997-1006.
19. Chen, Z.H., Zhang, G.L., Li, H.R., Luo, J.D., Li, Z.X., Chen, G.M., et al. (2012). A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72, 1443-1452.
20. Cheng, H.H., Mitchell, P.S., Kroh, E.M., Dowell, A.E., Chery, L., Siddiqui, J., et al. (2013). Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 8, e69239.
21. Chu, M., Chang, Y., Li, P., Guo, Y., Zhang, K., and Gao, W. (2014). Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells. Oncol Rep 31, 34-40.
22. Coppola, V., De Maria, R., and Bonci, D. (2010). MicroRNAs and prostate cancer. Endocr Relat cancer 17, F1-F17.
23. Corcoran, N.M., Casey, R.G., Hong, M.K., Pedersen, J., Connolly, S., Peters, J., et al. (2012). The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 110, 36-42.
24. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Blank, K., Broderick, G.A., et al. (1998). Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974.
25. Dahiya, N., Sherman-Baust, C.A., Wang, T.L., Davidson, B., Shih Ie, M., Zhang, Y., et al. (2008). MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3, e2436.
26. Dai, X., Chiang, Y., Wang, Z., Song, Y., Lu, C., Gao, P., et al. (2012). Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Rep 5, 1299-1304.
27. Dall'Era, M.A., Cooperberg, M.R., Chan, J.M., Davies, B.J., Albertsen, P.C., Klotz, L.H., et al. (2008). Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112, 1650-1659.
28. de Souza Rocha Simonini, P., Breiling, A., Gupta, N., Malekpour, M., Youns, M., Omranipour, R., et al. (2010). Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 70, 9175-9184.
29. DeVere White, R.W., Vinall, R.L., Tepper, C.G., and Shi, X.B. (2009). MicroRNAs and their potential for translation in prostate cancer. Urol Oncol 27, 307-311.
30. Ding, L., Xu, Y., Zhang, W., Deng, Y., Si, M., Du, Y., et al. (2010). MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20, 784-793.
31. Dong, Q., Meng, P., Wang, T., Qin, W., Qin, W., Wang, F., et al. (2010). MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5, e10147.
32. Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., Iruela-Arispe, M.L., Zhang, J., Matusik, R., et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238.
33. Erener, S., Mojibian, M., Fox, J.K., Denroche, H.C., and Kieffer, T.J. (2013). Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154, 603-608.
34. Faltejskova, P., Svoboda, M., Srutova, K., Mlcochova, J., Besse, A., Nekvindova, J., et al. (2012). Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16, 2655-2666.
35. Gandellini, P., Folini, M., and Zaffaroni, N. (2010). Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med 9, 212-218.
36. Garzon, R., Fabbri, M., Cimmino, A., Calin, G.A., and Croce, C.M. (2006). MicroRNA expression and function in cancer. Trends Mol Med 12, 580-587.
37. Gonzales, J.C., Fink, L.M., Goodman, O.B., Jr., Symanowski, J.T., Vogelzang, N.J., and Ward, D.C. (2011). Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9, 39-45.
38. Gordanpour, A., Nam, R.K., Sugar, L., Bacopulos, S., and Seth, A. (2012). MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR). J Vis Exp 63, e3874.
39. Haj-Ahmad, T.A., Abdalla, M.A., and Haj-Ahmad, Y. (2014). Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 5, 182-191.
40. Harris, T., Jimenez, L., Kawachi, N., Fan, J.B., Chen, J., Belbin, T., et al. (2012). Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180, 917-928.
41. Hawksworth, D., Ravindranath, L., Chen, Y., Furusato, B., Sesterhenn, I.A., McLeod, D.G., et al. (2010). Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13, 311-315.
42. Heinzelmann, J., Henning, B., Sanjmyatav, J., Posorski, N., Steiner, T., Wunderlich, H., et al. (2011). Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29, 367-373.
43. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
44. Jenkins, R.B., Qian, J., Lieber, M.M., and Bostwick, D.G. (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57, 524-531.
45. Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647.
46. Jung, H.M., Patel, R.S., Phillips, B.L., Wang, H., Cohen, D.M., Reinhold, W.C., et al. (2013). Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 24, 1638-1648, S1-S7.
47. Kong, D., Heath, E., Chen, W., Cher, M.L., Powell, I., Heilbrun, L., et al. (2012). Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 7, e33729.
48. Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673-677.
49. Kundu, S.D., Roehl, K.A., Yu, X., Antenor, J.A., Suarez, B.K., and Catalona, W.J. (2007). Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 177, 505-509.
50. Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., et al. (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47, 1955-1963.
51. Lee, H., Park, C.S., Deftereos, G., Morihara, J., Stern, J.E., Hawes, S.E., et al. (2012). MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 10, 174.
52. Lee, Y.S., and Dutta, A. (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21, 1025-1030.
53. Li, J., Shi, W., Gao, Y., Yang, B., Jing, X., Shan, S., et al. (2013). Analysis of microRNA expression profiles in human hepatitis B virus-related hepatocellular carcinoma. Clin Lab 59, 1009-1015.
54. Li, L.M., Hu, Z.B., Zhou, Z.X., Chen, X., Liu, F.Y., Zhang, J.F., et al. (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70, 9798-9807.
55. Li, T., Li, R.S., Li, Y.H., Zhong, S., Chen, Y.Y., Zhang, C.M., et al. (2012a). miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187, 1466-1472.
56. Li, Y., Jiang, Q., Xia, N., Yang, H., and Hu, C. (2012b). Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res 40, 1662-1669.
57. Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., et al. (2000). Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343, 78-85.
58. Lilja, H., Ulmert, D., and Vickers, A.J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev 8, 268-278.
59. Lin, S.L., Chiang, A., Chang, D., and Ying, S.Y. (2008). Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14, 417-424.
60. Ling, X.H., Han, Z.D., Xia, D., He, H.C., Jiang, F.N., Lin, Z.Y., et al. (2014). MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep 41, 2779-2788.
61. Lodes, M.J., Caraballo, M., Suciu, D., Munro, S., Kumar, A., and Anderson, B. (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4, e6229.
62. Loeb, S., and Catalona, W.J. (2008). What to do with an abnormal PSA test. Oncologist 13, 299-305.
63. Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
64. Lu, T.X., Lim, E.J., Wen, T., Plassard, A.J., Hogan, S.P., Martin, L.J., et al. (2012). MiR-375 is downregulated in epithelial cells after IL-13 stimulation and regulates an IL-13-induced epithelial transcriptome. Mucos Immunol 5, 388-396.
65. Lynn, F.C. (2009). Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 20, 452-459.
66. Mahn, R., Heukamp, L.C., Rogenhofer, S., von Ruecker, A., Muller, S.C., and Ellinger, J. (2011). Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77, 1265 e9-e16.
67. Martens-Uzunova, E.S., Jalava, S.E., Dits, N.F., van Leenders, G.J., Moller, S., Trapman, J., et al. (2012). Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31, 978-991.
68. Mathe, E.A., Nguyen, G.H., Bowman, E.D., Zhao, Y., Budhu, A., Schetter, A.J., et al. (2009). MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15, 6192-6200.
69. Mitchell, P. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105, 10513-10518.
70. Moltzahn, F., Olshen, A.B., Baehner, L., Peek, A., Fong, L., Stoppler, H., et al. (2011). Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71, 550-560.
71. Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., et al. (2012). MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 287, 1527-1537.
72. National Cancer Institute. (2014). Prostate-specific antigen (PSA) test. Available at www.cancer.gov.beckerproxy.wustl.edu/cancertopics/factsheet/detection/PSA (last accessed January 8, 2014).
73. Nguyen, H.C., Xie, W., Yang, M., Hsieh, C.L., Drouin, S., Lee, G.S., et al. (2013). Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73, 346-354.
74. Ozen, M., Creighton, C.J., Ozdemir, M., and Ittmann, M. (2008). Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27, 1788-1793.
75. Patel, A.A., Chen, M.H., Renshaw, A.A., and D'Amico AV. (2007). PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298, 1533-1538.
76. Peng, X., Guo, W., Liu, T., Wang, X., Tu, X., Xiong, D., et al. (2011). Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6, e20341.
77. Pepe, M.S., and Thompson, M.L. (2000). Combining diagnostic test results to increase accuracy. Biostatistics 1, 123-140.
78. Plata Bello, A., and Concepcion Masip, T. (2014). Prostate cancer epidemiology. Arch Esp Urol 67, 373-382.
79. Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tammela, T.L., and Visakorpi, T. (2007). MicroRNA expression profiling in prostate cancer. Cancer Res 67, 6130-6135.
80. Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E., et al. (2004). A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432, 226-230.
81. Prensner, J.R., Rubin, M.A., Wei, J.T., and Chinnaiyan, A.M. (2012). Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4, 127rv3.
82. Prueitt, R.L., Yi, M., Hudson, R.S., Wallace, T.A., Howe, T.M., Yfantis, H.G., et al. (2008). Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68, 1152-1164.
83. Ren, Q., Liang, J., Wei, J., Basturk, O., Wang, J., Daniels, G., et al. (2014). Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res 6, 329-339.
84. Ribas, J., and Lupold, S.E. (2010). The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 9, 923-929.
85. Ribas, J., Ni, X., Haffner, M., Wentzel, E.A., Salmasi, A.H., Chowdhury, W.H., et al. (2009). miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69, 7165-7169.
86. Schaefer, A., Jung, M., Miller, K., Lein, M., Kristiansen, G., Erbersdobler, A., et al. (2010a). Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 42, 749-758.
87. Schaefer, A., Jung, M., Mollenkopf, H.J., Wagner, I., Stephan, C., Jentzmik, F., et al. (2010b). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126, 1166-1176.
88. Schroder, F.H., Carter, H.B., Wolters, T., van den Bergh, R.C., Gosselaar, C., Bangma, C.H., et al. (2008). Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53, 468-477.
89. Schubert, M., Spahn, M., Kneitz, S., Scholz, C.J., Joniau, S., Stroebel, P., et al. (2013). Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One 8, e65064.
90. Selth, L.A., Townley, S., Gillis, J.L., Ochnik, A.M., Murti, K., Macfarlane, R.J., et al. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131, 652-661.
91. Shen, J., Hruby, G.W., McKiernan, J.M., Gurvich, I., Lipsky, M.J., Benson, M.C., et al. (2012). Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72, 1469-1477.
92. Song, H., Liu, Y., Pan, J., and Zhao, S.T. (2013). Expression profile analysis reveals putative prostate cancer-related microRNAs. Genet Mol Res 12, 4934-4943.
93. Spahn, M., Kneitz, S., Scholz, C.J., Stenger, N., Rudiger, T., Strobel, P., et al. (2010). Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127, 394-403.
94. Srivastava, A., Goldberger, H., Dimtchev, A., Ramalinga, M., Chijioke, J., Marian, C., et al. (2013). MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One 8, e76994.
95. Takayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie-Inoue, K., Ikeda, K., et al. (2011). Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30, 619-630.
96. Tang, X., Tang, G., and Ozcan, S. (2008). Role of microRNAs in diabetes. Biochim Biophys Acta 1779, 697-701.
97. Tanic, M., Yanowsky, K., Rodriguez-Antona, C., Andres, R., Marquez-Rodas, I., Osorio, A., et al. (2012). Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 7, e38847.
98. Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et al. (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med 349, 215-224.
99. Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350, 2239-2246.
100. Tsukamoto, Y., Nakada, C., Noguchi, T., Tanigawa, M., Nguyen, L.T., Uchida, T., et al. (2010). MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 70, 2339-2349.
101. Ulmert, D., Cronin, A.M., Bjork, T., O'Brien, M.F., Scardino, P.T., Eastham, J.A., et al. (2008). Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6, 6.
102. Vickers, A.J., Cronin, A.M., Bjork, T., Manjer, J., Nilsson, P.M., Dahlin, A., et al. (2010). Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341, c4521.
103. Wach, S., Nolte, E., Szczyrba, J., Stohr, R., Hartmann, A., Orntoft, T., et al. (2012). MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130, 611-621.
104. Wang, G., Zhang, H., He, H., Tong, W., Wang, B., Liao, G., et al. (2010). Up-regulation of microRNA in bladder tumor tissue is not common. Int Urol Nephrol 42, 95-102.
105. Watahiki, A., Wang, Y., Morris, J., Dennis, K., O'Dwyer, H.M., Gleave, M., et al. (2011). MicroRNAs associated with metastatic prostate cancer. PLoS One 6, e24950.
106. Westermann, A.M., Schmidt, D., Holdenrieder, S., Moritz, R., Semjonow, A., Schmidt, M., et al. (2014). Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Res 34, 665-669.
107. Xu, J., Li, C.X., Lv, J.Y., Li, Y.S., Xiao, Y., Shao, T.T., et al. (2011). Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer. Mol Cancer Ther 10, 1857-1866.
108. Yamakuchi, M., Ferlito, M., and Lowenstein, C.J. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105, 13421-13426.
109. Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N., et al. (2011). Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32, 583-588.
110. Zhang, H.L., Qin, X.J., Cao, D.L., Zhu, Y., Yao, X.D., Zhang, S.L., et al. (2013). An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl 15, 231-235.
111. Zhang, H.L., Yang, L.F., Zhu, Y., Yao, X.D., Zhang, S.L., Dai, B., et al. (2011). Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326-331.
112. Zhao, B., Han, H., Chen, J., Zhang, Z., Li, S., Fang, F., et al. (2014). MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett 342, 43-51.
113. Zhou, J., Song, S., Cen, J., Zhu, D., Li, D., and Zhang, Z. (2012). MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res 20, 197-203.